<?xml version='1.0' encoding='utf-8'?>
<document id="27821435"><sentence text="What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015." /><sentence text="As a follow up to previous reviews, the aim of the present analysis was to systematically examine all drug metabolism, transport, pharmacokinetics (PK), and drug-drug interaction (DDI) data available in the 33 new drug applications (NDAs) approved by the Food and Drug Administration (FDA) in 2015, using the University of Washington Drug Interaction Database, and to highlight the significant findings" /><sentence text=" In vitro, a majority of the new molecular entities (NMEs) were found to be substrates or inhibitors/inducers of at least one drug metabolizing enzyme or transporter" /><sentence text=" In vivo, 95 clinical DDI studies displayed positive PK interactions, with an area under the curve (AUC) ratio ≥ 1" /><sentence text="25 for inhibition or ≤ 0" /><sentence text="8 for induction" /><sentence text=" When NMEs were considered as victim drugs, 21 NMEs had at least one positive clinical DDI, with three NMEs shown to be sensitive substrates of CYP3A (AUC ratio ≥ 5 when coadministered with strong inhibitors): cobimetinib, isavuconazole (the active metabolite of prodrug isavuconazonium sulfate), and ivabradine"><entity charOffset="210-221" id="DDI-PubMed.27821435.s7.e0" text="cobimetinib" /><entity charOffset="223-236" id="DDI-PubMed.27821435.s7.e1" text="isavuconazole" /><entity charOffset="271-294" id="DDI-PubMed.27821435.s7.e2" text="isavuconazonium sulfate" /><entity charOffset="301-311" id="DDI-PubMed.27821435.s7.e3" text="ivabradine" /><pair ddi="false" e1="DDI-PubMed.27821435.s7.e0" e2="DDI-PubMed.27821435.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27821435.s7.e0" e2="DDI-PubMed.27821435.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27821435.s7.e0" e2="DDI-PubMed.27821435.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27821435.s7.e0" e2="DDI-PubMed.27821435.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27821435.s7.e1" e2="DDI-PubMed.27821435.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27821435.s7.e1" e2="DDI-PubMed.27821435.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27821435.s7.e1" e2="DDI-PubMed.27821435.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27821435.s7.e2" e2="DDI-PubMed.27821435.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27821435.s7.e2" e2="DDI-PubMed.27821435.s7.e3" /></sentence><sentence text=" As perpetrators, nine NMEs showed positive inhibition and three NMEs showed positive induction, with some of these interactions involving both enzymes and transporters" /><sentence text=" The most significant changes for inhibition and induction were observed with rolapitant, a moderate inhibitor of CYP2D6 and lumacaftor, a strong inducer of CYP3A" /><sentence text=" Physiologically based pharmacokinetics simulations and pharmacogenetics studies were used for six and eight NMEs, respectively, to inform dosing recommendations" /><sentence text=" The effects of hepatic or renal impairment on the drugs' PK were also evaluated to support drug administration in these specific populations" /><sentence text="" /></document>